Navigation Links
New MedPredict Report Assesses Current Outlook for Anticoagulants Market

Multi-Specialty Physician Panel Weighs in on Likely Positioning for Lilly/Daiichi's Prasugrel

SCOTTSDALE, Ariz., Feb. 20 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies developing anticoagulant therapies. This report is based on primary interviews conducted with cardiovascular experts from North America and Europe immediately following the American Society of Hematology (ASH) annual meeting.

"Anticoagulation therapy is being studied in a variety of settings, including elective and non-elective surgery, acute coronary syndrome, prevention and treatment of deep vein thrombosis/pulmonary embolism, secondary prevention of strokes in patients being treated for atrial fibrillation, and oncology," says Jeff Berk, MedPredict president. "Our Thought Leaders share their opinions on antithrombotics and antiplatelets driven by different patient populations and differing therapeutic goals."

The report addresses the following questions:

  • Which patient populations are most likely to be prescribed Effient (prasugrel), and how are physicians likely to balance efficacy versus bleeding risk? How does this vary by specialty?
  • Is daily oral anticoagulant therapy preferable to a monthly parenteral dose?
  • What do acute coronary syndrome treaters want that pharma is not currently providing?
  • How do different specialists view the strengths and weaknesses of the various anticoagulant therapies in development?

"Our panel reviews all of the key compounds in the pipeline and distills a massive amount of information down to the most critical insights drug developers should have for decision-making," according to Dr. Berk.

Companies mentioned in this report include: Astellas, AstraZeneca, Bayer-Schering, Bristol-Meyers Squibb, Daiichi Sankyo, GlaxoSmithKline, Lilly, Pfizer, Portola, Sanofi-Aventis, Schering-Plough, Takeda, The Medicines Company.

This report can be purchased by contacting MedPredict (

About MedPredict

MedPredict maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

SOURCE MedPredict
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiovascular Meds May Be Beneficial in Alzheimers Disease, According to MedPredict Report
2. MedPredict Publishes Two New Reports Providing Expert Analysis of Malignant Hematology Drug Development
3. Virginia Tech Report Has National Importance
4. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
5. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
6. Haemacure Reports Third Quarter 2007 Results
7. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
8. Biotech Finishes on a High in August, Burrill Report Says
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... ... eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, ... Medicine tests directly from their electronic medical record (EMR) without the need for ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... of workshops to discuss bioavailability and the need to integrate dose form selection ... in collaboration with OBN, the membership organization supporting and bringing together the UK’s ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... PRMA Plastic ... November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , ... wake up every day excited to rebuild lives and it’s an honor to have ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film Studios brings Final ... ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, ... giving users limitless opportunities to stylize and create designs quickly and easily, all ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of the ... to improve system efficiency and reliability. , The new Q-Suite 6 platform is based ... system avoids locking itself into a specific piece of software for many key components ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Therapeutic Drug Monitoring (TDM) Market: ... Intelligence, Emerging Opportunities"  report to their ... has announced the addition of the  ...
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
Breaking Medicine Technology: